TY - JOUR AU - Gaede, P. AU - Vedel, P. AU - Larsen, N. AU - Jensen, G. V. AU - Parving, H. H. AU - Pedersen, O. PY - 2003 DA - 2003// TI - Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes JO - N Engl J Med VL - 348 UR - https://doi.org/10.1056/NEJMoa021778 DO - 10.1056/NEJMoa021778 ID - Gaede2003 ER - TY - JOUR AU - Ott, C. AU - Schmid, A. AU - Toennes, S. W. AU - Ditting, T. AU - Veelken, R. AU - Uder, M. AU - Schmieder, R. E. PY - 2015 DA - 2015// TI - Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension JO - EuroIntervention VL - 11 UR - https://doi.org/10.4244/EIJV11I1A19 DO - 10.4244/EIJV11I1A19 ID - Ott2015 ER - TY - JOUR AU - Laurent, S. AU - Cockcroft, J. AU - Bortel, L. AU - Boutouyrie, P. AU - Giannattasio, C. AU - Hayoz, D. AU - Pannier, B. AU - Vlachopoulos, C. AU - Wilkinson, I. AU - Struijker-Boudier, H. PY - 2006 DA - 2006// TI - Expert consensus document on arterial stiffness: methodological issues and clinical applications JO - Eur Heart J VL - 27 UR - https://doi.org/10.1093/eurheartj/ehl254 DO - 10.1093/eurheartj/ehl254 ID - Laurent2006 ER - TY - JOUR AU - Mancia, G. AU - Fagard, R. AU - Narkiewicz, K. AU - Redon, J. AU - Zanchetti, A. AU - Bohm, M. AU - Christiaens, T. AU - Cifkova, R. AU - Backer, G. AU - Dominiczak, A. PY - 2013 DA - 2013// TI - 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) JO - J Hypertens VL - 31 UR - https://doi.org/10.1097/01.hjh.0000431740.32696.cc DO - 10.1097/01.hjh.0000431740.32696.cc ID - Mancia2013 ER - TY - JOUR AU - Weber, T. AU - Wassertheurer, S. AU - Rammer, M. AU - Haiden, A. AU - Hametner, B. AU - Eber, B. PY - 2012 DA - 2012// TI - Wave reflections, assessed with a novel method for pulse wave separation, are associated with end-organ damage and clinical outcomes JO - Hypertension VL - 60 UR - https://doi.org/10.1161/HYPERTENSIONAHA.112.194571 DO - 10.1161/HYPERTENSIONAHA.112.194571 ID - Weber2012 ER - TY - JOUR AU - Roden, M. AU - Merker, L. AU - Christiansen, A. V. AU - Roux, F. AU - Salsali, A. AU - Kim, G. AU - Stella, P. AU - Woerle, H. J. AU - Broedl, U. C. PY - 2015 DA - 2015// TI - investigators E-REM: Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial JO - Cardiovasc Diabetol VL - 14 UR - https://doi.org/10.1186/s12933-015-0314-0 DO - 10.1186/s12933-015-0314-0 ID - Roden2015 ER - TY - JOUR AU - Ott, C. AU - Jumar, A. AU - Striepe, K. AU - Friedrich, S. AU - Karg, M. V. AU - Bramlage, P. AU - Schmieder, R. E. PY - 2017 DA - 2017// TI - A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation JO - Cardiovasc Diabetol VL - 16 UR - https://doi.org/10.1186/s12933-017-0510-1 DO - 10.1186/s12933-017-0510-1 ID - Ott2017 ER - TY - JOUR AU - Zinman, B. AU - Wanner, C. AU - Lachin, J. M. AU - Fitchett, D. AU - Bluhmki, E. AU - Hantel, S. AU - Mattheus, M. AU - Devins, T. AU - Johansen, O. E. AU - Woerle, H. J. PY - 2015 DA - 2015// TI - Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504720 DO - 10.1056/NEJMoa1504720 ID - Zinman2015 ER - TY - JOUR AU - Striepe, K. AU - Jumar, A. AU - Ott, C. AU - Karg, M. V. AU - Schneider, M. P. AU - Kannenkeril, D. AU - Schmieder, R. E. PY - 2017 DA - 2017// TI - Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus JO - Circulation VL - 136 UR - https://doi.org/10.1161/CIRCULATIONAHA.117.029529 DO - 10.1161/CIRCULATIONAHA.117.029529 ID - Striepe2017 ER - TY - JOUR AU - Inzucchi, S. E. AU - Zinman, B. AU - Fitchett, D. AU - Wanner, C. AU - Ferrannini, E. AU - Schumacher, M. AU - Schmoor, C. AU - Ohneberg, K. AU - Johansen, O. E. AU - George, J. T. PY - 2018 DA - 2018// TI - How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial JO - Diabetes Care VL - 41 UR - https://doi.org/10.2337/dc17-1096 DO - 10.2337/dc17-1096 ID - Inzucchi2018 ER - TY - JOUR AU - Hametner, B. AU - Wassertheurer, S. AU - Kropf, J. AU - Mayer, C. AU - Eber, B. AU - Weber, T. PY - 2013 DA - 2013// TI - Oscillometric estimation of aortic pulse wave velocity: comparison with intra-aortic catheter measurements JO - Blood pressure monitoring VL - 18 UR - https://doi.org/10.1097/MBP.0b013e3283614168 DO - 10.1097/MBP.0b013e3283614168 ID - Hametner2013 ER - TY - JOUR AU - Feistritzer, H. J. AU - Reinstadler, S. J. AU - Klug, G. AU - Kremser, C. AU - Seidner, B. AU - Esterhammer, R. AU - Schocke, M. F. AU - Franz, W. M. AU - Metzler, B. PY - 2015 DA - 2015// TI - Comparison of an oscillometric method with cardiac magnetic resonance for the analysis of aortic pulse wave velocity JO - PLoS ONE VL - 10 UR - https://doi.org/10.1371/journal.pone.0116862 DO - 10.1371/journal.pone.0116862 ID - Feistritzer2015 ER - TY - JOUR AU - Wanner, C. AU - Inzucchi, S. E. AU - Zinman, B. PY - 2016 DA - 2016// TI - Empagliflozin and progression of kidney disease in type 2 diabetes JO - N Engl J Med VL - 375 ID - Wanner2016 ER - TY - JOUR AU - Fitchett, D. AU - Zinman, B. AU - Wanner, C. AU - Lachin, J. M. AU - Hantel, S. AU - Salsali, A. AU - Johansen, O. E. AU - Woerle, H. J. AU - Broedl, U. C. AU - Inzucchi, S. E. PY - 2016 DA - 2016// TI - Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial JO - Eur Heart J VL - 37 UR - https://doi.org/10.1093/eurheartj/ehv728 DO - 10.1093/eurheartj/ehv728 ID - Fitchett2016 ER - TY - JOUR AU - Marx, N. AU - McGuire, D. K. PY - 2016 DA - 2016// TI - Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus JO - Eur Heart J VL - 37 UR - https://doi.org/10.1093/eurheartj/ehw110 DO - 10.1093/eurheartj/ehw110 ID - Marx2016 ER - TY - JOUR AU - Chilton, R. AU - Tikkanen, I. AU - Cannon, C. P. AU - Crowe, S. AU - Woerle, H. J. AU - Broedl, U. C. AU - Johansen, O. E. PY - 2015 DA - 2015// TI - Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes JO - Diabetes Obes Metab VL - 17 UR - https://doi.org/10.1111/dom.12572 DO - 10.1111/dom.12572 ID - Chilton2015 ER - TY - JOUR AU - Palatini, P. AU - Casiglia, E. AU - Gasowski, J. AU - Gluszek, J. AU - Jankowski, P. AU - Narkiewicz, K. AU - Saladini, F. AU - Stolarz-Skrzypek, K. AU - Tikhonoff, V. AU - Bortel, L. PY - 2011 DA - 2011// TI - Arterial stiffness, central hemodynamics, and cardiovascular risk in hypertension JO - Vasc Health Risk Manag VL - 7 UR - https://doi.org/10.2147/VHRM.S25270 DO - 10.2147/VHRM.S25270 ID - Palatini2011 ER - TY - JOUR AU - Roman, M. J. AU - Devereux, R. B. AU - Kizer, J. R. AU - Lee, E. T. AU - Galloway, J. M. AU - Ali, T. AU - Umans, J. G. AU - Howard, B. V. PY - 2007 DA - 2007// TI - Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study JO - Hypertension VL - 50 UR - https://doi.org/10.1161/HYPERTENSIONAHA.107.089078 DO - 10.1161/HYPERTENSIONAHA.107.089078 ID - Roman2007 ER - TY - JOUR AU - Wang, K. L. AU - Cheng, H. M. AU - Chuang, S. Y. AU - Spurgeon, H. A. AU - Ting, C. T. AU - Lakatta, E. G. AU - Yin, F. C. AU - Chou, P. AU - Chen, C. H. PY - 2009 DA - 2009// TI - Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? JO - J Hypertens VL - 27 UR - https://doi.org/10.1097/HJH.0b013e3283220ea4 DO - 10.1097/HJH.0b013e3283220ea4 ID - Wang2009 ER - TY - JOUR AU - Roman, M. J. AU - Okin, P. M. AU - Kizer, J. R. AU - Lee, E. T. AU - Howard, B. V. AU - Devereux, R. B. PY - 2010 DA - 2010// TI - Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study JO - J Hypertens VL - 28 UR - https://doi.org/10.1097/HJH.0b013e328333d228 DO - 10.1097/HJH.0b013e328333d228 ID - Roman2010 ER - TY - JOUR AU - Solini, A. AU - Giannini, L. AU - Seghieri, M. AU - Vitolo, E. AU - Taddei, S. AU - Ghiadoni, L. AU - Bruno, R. M. PY - 2017 DA - 2017// TI - Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study JO - Cardiovasc Diabetol VL - 16 UR - https://doi.org/10.1186/s12933-017-0621-8 DO - 10.1186/s12933-017-0621-8 ID - Solini2017 ER - TY - JOUR AU - Pfeifer, M. AU - Townsend, R. R. AU - Davies, M. J. AU - Vijapurkar, U. AU - Ren, J. PY - 2017 DA - 2017// TI - Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis JO - Cardiovasc Diabetol VL - 16 UR - https://doi.org/10.1186/s12933-017-0511-0 DO - 10.1186/s12933-017-0511-0 ID - Pfeifer2017 ER - TY - JOUR AU - Bekki, M. AU - Tahara, N. AU - Tahara, A. AU - Igata, S. AU - Honda, A. AU - Sugiyama, Y. AU - Nakamura, T. AU - Sun, J. AU - Kumashiro, Y. AU - Matsui, T. PY - 2018 DA - 2018// TI - Switching dipeptidyl peptidase-4 inhibitors to tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2 improves arterial stiffness evaluated by cardio-ankle vascular index in patients with type 2 diabetes: a pilot study JO - Curr Vasc Pharmacol UR - https://doi.org/10.2174/1570161116666180515154555 DO - 10.2174/1570161116666180515154555 ID - Bekki2018 ER - TY - JOUR AU - Neal, B. AU - Perkovic, V. AU - Matthews, D. R. PY - 2017 DA - 2017// TI - Canagliflozin and cardiovascular and renal events in type 2 diabetes JO - N Engl J Med VL - 377 ID - Neal2017 ER - TY - JOUR AU - Uthman, L. AU - Baartscheer, A. AU - Schumacher, C. A. AU - Fiolet, J. W. T. AU - Kuschma, M. C. AU - Hollmann, M. W. AU - Coronel, R. AU - Weber, N. C. AU - Zuurbier, C. J. PY - 2018 DA - 2018// TI - Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients JO - Front Physiol VL - 9 UR - https://doi.org/10.3389/fphys.2018.01575 DO - 10.3389/fphys.2018.01575 ID - Uthman2018 ER - TY - JOUR AU - Oelze, M. AU - Kroller-Schon, S. AU - Welschof, P. AU - Jansen, T. AU - Hausding, M. AU - Mikhed, Y. AU - Stamm, P. AU - Mader, M. AU - Zinssius, E. AU - Agdauletova, S. PY - 2014 DA - 2014// TI - The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity JO - PLoS ONE VL - 9 UR - https://doi.org/10.1371/journal.pone.0112394 DO - 10.1371/journal.pone.0112394 ID - Oelze2014 ER - TY - JOUR AU - Andreadou, I. AU - Efentakis, P. AU - Balafas, E. AU - Togliatto, G. AU - Davos, C. H. AU - Varela, A. AU - Dimitriou, C. A. AU - Nikolaou, P. E. AU - Maratou, E. AU - Lambadiari, V. PY - 2017 DA - 2017// TI - Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects JO - Front Physiol VL - 8 UR - https://doi.org/10.3389/fphys.2017.01077 DO - 10.3389/fphys.2017.01077 ID - Andreadou2017 ER - TY - JOUR AU - Tanajak, P. AU - Sa-Nguanmoo, P. AU - Sivasinprasasn, S. AU - Thummasorn, S. AU - Siri-Angkul, N. AU - Chattipakorn, S. C. AU - Chattipakorn, N. PY - 2018 DA - 2018// TI - Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury JO - J Endocrinol VL - 236 UR - https://doi.org/10.1530/JOE-17-0457 DO - 10.1530/JOE-17-0457 ID - Tanajak2018 ER - TY - JOUR AU - Lahnwong, S. AU - Chattipakorn, S. C. AU - Chattipakorn, N. PY - 2018 DA - 2018// TI - Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors JO - Cardiovasc Diabetol VL - 17 UR - https://doi.org/10.1186/s12933-018-0745-5 DO - 10.1186/s12933-018-0745-5 ID - Lahnwong2018 ER - TY - JOUR AU - Lytvyn, Y. AU - Bjornstad, P. AU - Udell, J. A. AU - Lovshin, J. A. AU - Cherney, D. Z. I. PY - 2017 DA - 2017// TI - Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials JO - Circulation VL - 136 UR - https://doi.org/10.1161/CIRCULATIONAHA.117.030012 DO - 10.1161/CIRCULATIONAHA.117.030012 ID - Lytvyn2017 ER - TY - JOUR AU - Lee, D. M. AU - Battson, M. L. AU - Jarrell, D. K. AU - Hou, S. AU - Ecton, K. E. AU - Weir, T. L. AU - Gentile, C. L. PY - 2018 DA - 2018// TI - SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice JO - Cardiovasc Diabetol VL - 17 UR - https://doi.org/10.1186/s12933-018-0708-x DO - 10.1186/s12933-018-0708-x ID - Lee2018 ER - TY - JOUR AU - Pabel, S. AU - Wagner, S. AU - Bollenberg, H. AU - Bengel, P. AU - Kovacs, A. AU - Schach, C. AU - Tirilomis, P. AU - Mustroph, J. AU - Renner, A. AU - Gummert, J. PY - 2018 DA - 2018// TI - Empagliflozin directly improves diastolic function in human heart failure JO - Eur J Heart Fail VL - 20 UR - https://doi.org/10.1002/ejhf.1328 DO - 10.1002/ejhf.1328 ID - Pabel2018 ER - TY - JOUR AU - Aroor, A. R. AU - Das, N. A. AU - Carpenter, A. J. AU - Habibi, J. AU - Jia, G. AU - Ramirez-Perez, F. I. AU - Martinez-Lemus, L. AU - Manrique-Acevedo, C. M. AU - Hayden, M. R. AU - Duta, C. PY - 2018 DA - 2018// TI - Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury JO - Cardiovasc Diabetol VL - 17 UR - https://doi.org/10.1186/s12933-018-0750-8 DO - 10.1186/s12933-018-0750-8 ID - Aroor2018 ER - TY - JOUR AU - Ojima, A. AU - Matsui, T. AU - Nishino, Y. AU - Nakamura, N. AU - Yamagishi, S. PY - 2015 DA - 2015// TI - Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis JO - Hormone Metab Res = Hormon- und Stoffwechselforschung = Hormones et metabolisme VL - 47 UR - https://doi.org/10.1055/s-0034-1395609 DO - 10.1055/s-0034-1395609 ID - Ojima2015 ER - TY - JOUR AU - Xu, L. AU - Nagata, N. AU - Nagashimada, M. AU - Zhuge, F. AU - Ni, Y. AU - Chen, G. AU - Mayoux, E. AU - Kaneko, S. AU - Ota, T. PY - 2017 DA - 2017// TI - SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice JO - EBioMedicine VL - 20 UR - https://doi.org/10.1016/j.ebiom.2017.05.028 DO - 10.1016/j.ebiom.2017.05.028 ID - Xu2017 ER - TY - JOUR AU - Leng, W. AU - Ouyang, X. AU - Lei, X. AU - Wu, M. AU - Chen, L. AU - Wu, Q. AU - Deng, W. AU - Liang, Z. PY - 2016 DA - 2016// TI - The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE(−/−) mice JO - Mediators Inflamm VL - 2016 UR - https://doi.org/10.1155/2016/6305735 DO - 10.1155/2016/6305735 ID - Leng2016 ER - TY - JOUR AU - Shigiyama, F. AU - Kumashiro, N. AU - Miyagi, M. AU - Ikehara, K. AU - Kanda, E. AU - Uchino, H. AU - Hirose, T. PY - 2017 DA - 2017// TI - Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study JO - Cardiovasc Diabetol VL - 16 UR - https://doi.org/10.1186/s12933-017-0564-0 DO - 10.1186/s12933-017-0564-0 ID - Shigiyama2017 ER - TY - JOUR AU - Wanner, C. PY - 2017 DA - 2017// TI - EMPA-REG OUTCOME: the nephrologist’s point of view JO - Am J Cardiol VL - 120 UR - https://doi.org/10.1016/j.amjcard.2017.05.012 DO - 10.1016/j.amjcard.2017.05.012 ID - Wanner2017 ER - TY - JOUR AU - Ferrannini, E. AU - Baldi, S. AU - Frascerra, S. AU - Astiarraga, B. AU - Barsotti, E. AU - Clerico, A. AU - Muscelli, E. PY - 2017 DA - 2017// TI - Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes JO - Diabetes Care VL - 40 UR - https://doi.org/10.2337/dc16-2724 DO - 10.2337/dc16-2724 ID - Ferrannini2017 ER - TY - JOUR AU - Irace, C. AU - Casciaro, F. AU - Scavelli, F. B. AU - Oliverio, R. AU - Cutruzzola, A. AU - Cortese, C. AU - Gnasso, A. PY - 2018 DA - 2018// TI - Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy JO - Cardiovasc Diabetol VL - 17 UR - https://doi.org/10.1186/s12933-018-0695-y DO - 10.1186/s12933-018-0695-y ID - Irace2018 ER - TY - JOUR AU - Umpierrez, G. E. PY - 2017 DA - 2017// TI - Diabetes: SGLT2 inhibitors and diabetic ketoacidosis—a growing concern JO - Nat Rev Endocrinol VL - 13 UR - https://doi.org/10.1038/nrendo.2017.77 DO - 10.1038/nrendo.2017.77 ID - Umpierrez2017 ER - TY - JOUR AU - Briand, F. AU - Mayoux, E. AU - Brousseau, E. AU - Burr, N. AU - Urbain, I. AU - Costard, C. AU - Mark, M. AU - Sulpice, T. PY - 2016 DA - 2016// TI - Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism JO - Diabetes VL - 65 UR - https://doi.org/10.2337/db16-0049 DO - 10.2337/db16-0049 ID - Briand2016 ER -